Income Statement Thiogenesis Therapeutics, Corp. OTC Markets

Stocks

TTIPF

CA88410L1022

Biotechnology & Medical Research

Market Closed - OTC Markets 09:54:44 2026-09-14 EDT			5-day change	1st Jan Change
0.3671 ^USD	-12.57%		-12.57%	-37.08%

08-06	Thiogenesis Therapeutics, Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
07-13	Thiogenesis Therapeutics Receives Fda Rare Pediatric Disease Designation for Tti-0102 for the Treatment of Leigh Syndrome	CI

0f4f5054f9856b9720a38329d5d8.O7kboYMhAbiMPMLVoV0tlaRdK-jVOQd5razYXoPScIk.dYts19YWc9XYD_qi6xdB59VweKmHQGsV3secC8KbOr5tyC7n9hhx1MgLmw

Published financial data: THIOGENESIS THERAPEUTICS, CORP.

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: December	2021 (USD)	2022 (CAD)	2023 (CAD)	2024 (CAD)	2025 (CAD)
Selling General & Admin Expenses, Total	256K	933K	1.04M	1.36M	1.63M
Stock-Based Compensation (IS)	5.26K	-	-	-	-
R&D Expenses	1.07M	1.08M	4.16M	2.22M	5.77M
Other Operating Expenses, Total	1.33M	2.01M	5.21M	3.58M	7.4M
Operating Income	-1.33M	-2.01M	-5.21M	-3.58M	-7.4M
Interest Expense, Total	-2.43K	-4.12K	-	-	-
Interest And Investment Income	39	6.18K	171K	200K	48.72K
Net Interest Expenses	-2.4K	2.06K	171K	200K	48.72K
Currency Exchange Gains (Loss)	-	-	-28.16K	233K	-79.57K
Other Non Operating Income (Expenses)	366K	95.6K	-	-	-
EBT, Excl. Unusual Items	-967K	-1.91M	-5.06M	-3.15M	-7.43M
Other Unusual Items	-	-2.01M	-	-	-
EBT, Incl. Unusual Items	-967K	-3.92M	-5.06M	-3.15M	-7.43M
Earnings From Continuing Operations	-967K	-3.92M	-5.06M	-3.15M	-7.43M
Net Income to Company	-967K	-3.92M	-5.06M	-3.15M	-7.43M
Net Income - (IS)	-967K	-3.92M	-5.06M	-3.15M	-7.43M
Net Income to Common Incl Extra Items	-967K	-3.92M	-5.06M	-3.15M	-7.43M
Net Income to Common Excl. Extra Items	-967K	-3.92M	-5.06M	-3.15M	-7.43M
Per Share Items
Net EPS - Basic	-0.08	-0.16	-0.13	-0.07	-0.15
Basic EPS - Continuing Operations	-0.08	-0.16	-0.13	-0.07	-0.15
Basic Weighted Average Shares Outstanding	11.56M	25.29M	39.13M	45.36M	48.58M
Net EPS - Diluted	-0.08	-0.16	-0.13	-0.07	-0.15
Diluted EPS - Continuing Operations	-0.08	-0.16	-0.13	-0.07	-0.15
Diluted Weighted Average Shares Outstanding	11.56M	25.29M	39.13M	45.36M	48.58M
Normalized Basic EPS	-0.05	-0.05	-0.08	-0.04	-0.1
Normalized Diluted EPS	-0.05	-0.05	-0.08	-0.04	-0.1
Supplemental Items
EBITA	-1.33M	-2.01M	-5.21M	-3.58M	-7.4M
EBIT	-1.33M	-2.01M	-5.21M	-3.58M	-7.4M
Normalized Net Income	-604K	-1.19M	-3.16M	-1.97M	-4.64M
Supplemental Operating Expense Items
General and Administrative Expenses	-	933K	1.04M	1.36M	1.63M
Research And Development Expense From Footnotes	1.07M	1.08M	4.16M	2.22M	5.77M
Stock-Based Comp., R&D Exp. (Total)	-	202K	201K	73.64K	196K
Stock-Based Comp., G&A Exp. (Total)	-	322K	280K	275K	578K
Stock-Based Comp., Other (Total)	5.26K	-	-	-	-
Total Stock-Based Compensation	5.26K	524K	481K	349K	774K

Fiscal Period: December	2021 (USD)	2022 (CAD)	2023 (CAD)	2024 (CAD)	2025 (CAD)
Assets
Cash And Equivalents	49.33K	6.2M	7.08M	3.85M	1.62M
Total Cash And Short Term Investments	49.33K	6.2M	7.08M	3.85M	1.62M
Other Receivables	133K	55.99K	85.32K	87.93K	76.77K
Total Receivables	133K	55.99K	85.32K	87.93K	76.77K
Prepaid Expenses	-	38.62K	81.38K	47.6K	122K
Total Current Assets	182K	6.29M	7.24M	3.98M	1.81M
Total Assets	182K	6.29M	7.24M	3.98M	1.81M
Liabilities
Accounts Payable, Total	533K	307K	1.67M	558K	1.24M
Accrued Expenses, Total	4.36K	-	42.52K	-	-
Short-term Borrowings	364K	-	-	-	-
Other Current Liabilities	119K	-	-	-	-
Total Current Liabilities	1.02M	307K	1.71M	558K	1.24M
Total Liabilities	1.02M	307K	1.71M	558K	1.24M
Common Stock, Total	1.2K	11.13M	15.01M	16.14M	19.92M
Additional Paid In Capital	858K	1.06M	-	-	-
Retained Earnings	-1.69M	-6.18M	-11.14M	-14.28M	-21.71M
Comprehensive Income and Other	-3.16K	-22.31K	1.66M	1.57M	2.36M
Total Common Equity	-838K	5.98M	5.53M	3.43M	574K
Total Equity	-838K	5.98M	5.53M	3.43M	574K
Total Liabilities And Equity	182K	6.29M	7.24M	3.98M	1.81M
Supplemental Items
ECS Total Shares Outstanding on Filing Date	12M	38.86M	44.57M	46.02M	51.84M
ECS Total Common Shares Outstanding	12M	38.86M	44.57M	46.02M	51.84M
Book Value / Share	-0.07	0.15	0.12	0.07	0.01
Tangible Book Value	-838K	5.98M	5.53M	3.43M	574K
Tangible Book Value Per Share	-0.07	0.15	0.12	0.07	0.01
Total Debt	364K	0	0	0	0
Net Debt	315K	-6.2M	-7.08M	-3.85M	-1.62M
Account Code - Inventory Valuation	3	3	3	3	3

Fiscal Period: December	2021 (USD)	2022 (CAD)	2023 (CAD)	2024 (CAD)	2025 (CAD)
Net Income	-967K	-3.92M	-5.06M	-3.15M	-7.43M
Stock-Based Compensation (CF)	5.26K	524K	481K	349K	774K
Other Operating Activities, Total	-51.89K	1.88M	-	-	-
Change In Accounts Receivable	-9.37K	-7.99K	-64.07K	-2.61K	11.16K
Change In Accounts Payable	506K	-643K	1.41M	-1.15M	683K
Change in Other Net Operating Assets	-97.42K	81.85K	-8.01K	33.78K	-74.64K
Cash from Operations	-614K	-2.09M	-3.25M	-3.92M	-6.03M
Cash Acquisitions	-	107K	-	-	-
Cash from Investing	-	107K	-	-	-
Short Term Debt Issued, Total	113K	-	-	-	-
Total Debt Issued	113K	-	-	-	-
Short Term Debt Repaid, Total	-	-175K	-	-	-
Total Debt Repaid	-	-175K	-	-	-
Issuance of Common Stock	537K	5M	4.12M	723K	3.81M
Other Financing Activities, Total	-	3.31M	-	-	-
Cash from Financing	651K	8.13M	4.12M	723K	3.81M
Foreign Exchange Rate Adjustments	-2.54K	-10.98K	7.58K	-31.27K	-10.88K
Net Change in Cash	34.26K	6.13M	880K	-3.23M	-2.23M
Supplemental Items
Levered Free Cash Flow	-309K	-1.18M	-1.44M	-3.01M	-3.23M
Unlevered Free Cash Flow	-308K	-1.18M	-1.44M	-3.01M	-3.23M
Change In Net Working Capital	-518K	450K	-1.33M	1.12M	-619K
Net Debt Issued / Repaid	113K	-175K	-	-	-

Fiscal Period: December	2021 (USD)	2022 (CAD)	2023 (CAD)	2024 (CAD)	2025 (CAD)
Profitability
Return on Assets	-744.63	-38.51	-48.08	-39.85	-159.43
Return on Total Capital	359.12	-46.65	-56.52	-49.96	-231.11
Return On Equity %	179.33	-159.48	-87.95	-70.25	-371.31
Return on Common Equity	179.33	-159.48	-87.95	-70.25	-371.31
Short Term Liquidity
Current Ratio	0.18	20.48	4.23	7.14	1.46
Quick Ratio	0.18	20.35	4.18	7.05	1.36
Operating Cash Flow to Current Liabilities	-0.6	-6.8	-1.9	-7.03	-4.86
Long Term Solvency
Total Debt/Equity	-43.48	-	-	-	-
Total Debt / Total Capital	-76.93	-	-	-	-
Total Liabilities / Total Assets	559.93	4.88	23.65	14	68.35
EBIT / Interest Expense	-546.5	-487.26	-	-	-
Growth Over Prior Year
EBITA, 1 Yr. Growth %	180.87	20.12	159.14	-31.25	106.61
EBIT, 1 Yr. Growth %	180.87	20.12	159.14	-31.25	106.61
Earnings From Cont. Operations, 1 Yr. Growth %	102.98	222.12	29.02	-37.87	136.07
Net Income, 1 Yr. Growth %	102.98	222.12	29.02	-37.87	136.07
Normalized Net Income, 1 Yr. Growth %	102.99	56.89	164.9	-37.87	136.07
Diluted EPS Before Extra, 1 Yr. Growth %	75.65	47.18	-16.61	-46.4	120.41
Total Assets, 1 Yr. Growth %	342.95	2.62K	15.14	-45	-54.44
Tangible Book Value, 1 Yr. Growth %	248.51	-663.29	-7.58	-38.06	-83.23
Common Equity, 1 Yr. Growth %	248.51	-663.29	-7.58	-38.06	-83.23
Cash From Operations, 1 Yr. Growth %	64.53	172.05	55.45	20.69	53.87
Levered Free Cash Flow, 1 Yr. Growth %	-	209.35	21.53	109.27	7.19
Unlevered Free Cash Flow, 1 Yr. Growth %	-	210.2	21.8	109.27	7.19
Compound Annual Growth Rate Over Two Years
EBITA, 2 Yr. CAGR %	-	77.04	76.43	33.48	19.19
EBIT, 2 Yr. CAGR %	-	77.04	76.43	33.48	19.19
Earnings From Cont. Operations, 2 Yr. CAGR %	-	146.73	103.86	-10.47	21.11
Net Income, 2 Yr. CAGR %	-	146.73	103.86	-10.47	21.11
Normalized Net Income, 2 Yr. CAGR %	-	72.19	103.86	28.29	21.11
Diluted EPS Before Extra, 2 Yr. CAGR %	-	55.14	10.79	-33.15	8.69
Total Assets, 2 Yr. CAGR %	-	963.09	459.98	-20.42	-49.94
Tangible Book Value, 2 Yr. CAGR %	-	328.83	128.17	-24.34	-67.77
Common Equity, 2 Yr. CAGR %	-	328.83	128.17	-24.34	-67.77
Cash From Operations, 2 Yr. CAGR %	-	103.45	105.65	36.97	36.27
Levered Free Cash Flow, 2 Yr. CAGR %	-	-	93.9	59.48	49.78
Unlevered Free Cash Flow, 2 Yr. CAGR %	-	-	94.38	59.65	49.78
Compound Annual Growth Rate Over Three Years
EBITA, 3 Yr. CAGR %	-	-	102.66	28.87	54.4
EBIT, 3 Yr. CAGR %	-	-	102.66	28.87	54.4
Earnings From Cont. Operations, 3 Yr. CAGR %	-	-	100.41	37.19	23.69
Net Income, 3 Yr. CAGR %	-	-	100.41	37.19	23.69
Normalized Net Income, 3 Yr. CAGR %	-	-	100.41	37.19	57.21
Diluted EPS Before Extra, 3 Yr. CAGR %	-	-	27.18	-13.03	-0.5
Total Assets, 3 Yr. CAGR %	-	-	410.91	158.36	-33.92
Tangible Book Value, 3 Yr. CAGR %	-	-	159.22	47.74	-54.21
Common Equity, 3 Yr. CAGR %	-	-	159.22	47.74	-54.21
Cash From Operations, 3 Yr. CAGR %	-	-	87.52	72.18	42.39
Levered Free Cash Flow, 3 Yr. CAGR %	-	-	-	98.89	39.7
Unlevered Free Cash Flow, 3 Yr. CAGR %	-	-	-	99.22	39.8
Compound Annual Growth Rate Over Five Years
EBITA, 5 Yr. CAGR %	-	-	-	-	62.67
EBIT, 5 Yr. CAGR %	-	-	-	-	62.67
Earnings From Cont. Operations, 5 Yr. CAGR %	-	-	-	-	62.62
Net Income, 5 Yr. CAGR %	-	-	-	-	62.62
Normalized Net Income, 5 Yr. CAGR %	-	-	-	-	62.62
Diluted EPS Before Extra, 5 Yr. CAGR %	-	-	-	-	18.54
Total Assets, 5 Yr. CAGR %	-	-	-	-	100.23
Tangible Book Value, 5 Yr. CAGR %	-	-	-	-	11.75
Common Equity, 5 Yr. CAGR %	-	-	-	-	11.75
Cash From Operations, 5 Yr. CAGR %	-	-	-	-	63.81